Home
MRSN
MRSN News

Latest Mersana Therapeutics Inc. (MRSN) News on September 9, 2025

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

GlobeNewswire

3 months ago

Mersana Therapeutics Reports Additional Positive Interim Phase 1 Clinical Data for Emi-Le in Oral Presentation at 2025 ASCO Annual Meeting

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

4 months ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

MT Newswires

4 months ago

Truist Raises Price Target on Mersana Therapeutics to $10 From $9, Keeps Buy Rating

Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...

GuruFocus.com

4 months ago

Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Call Highlights: Strategic Restructuring and ...

Thomson Reuters StreetEvents

4 months ago

Q1 2025 Mersana Therapeutics Inc Earnings Call

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

GlobeNewswire

4 months ago

CORRECTION - Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Zacks

4 months ago

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

GlobeNewswire

4 months ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2025 Financial Results

Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For

GuruFocus.com

4 months ago

Mersana Therapeutics Inc (MRSN) Q1 2025 Earnings Report Preview: What to Look For

MT Newswires

4 months ago

Wedbush Cuts Price Target on Mersana Therapeutics to $3 From $4, Maintains Outperform Rating

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

GlobeNewswire

4 months ago

Mersana Therapeutics Announces Strategic Restructuring and Reprioritization Plan Focused on Advancing Emi-Le in Triple-Negative Breast Cancer

Bluebird pleads for deal support; Unity, Mersana lay off staff

BioPharma Dive

4 months ago

Bluebird pleads for deal support; Unity, Mersana lay off staff

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

GlobeNewswire

5 months ago

Mersana Therapeutics Announces Upcoming Emi-Le Oral and Poster Presentations at ASCO 2025 Annual Meeting

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

5 months ago

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

GlobeNewswire

5 months ago

Mersana Therapeutics Announces Upcoming Oral Presentation of Emi-Le Clinical Data at European Society for Medical Oncology (ESMO) Breast Cancer 2025 Annual Congress

Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates

Simply Wall St.

6 months ago

Earnings Update: Mersana Therapeutics, Inc. (NASDAQ:MRSN) Just Reported And Analysts Are Boosting Their Estimates

Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts

Simply Wall St.

6 months ago

Industry Analysts Just Made A Captivating Upgrade To Their Mersana Therapeutics, Inc. (NASDAQ:MRSN) Revenue Forecasts

Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations

Simply Wall St.

6 months ago

Mersana Therapeutics Full Year 2024 Earnings: Beats Expectations

Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com

6 months ago

Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings Call Highlights: Strategic Advances and ...

Thomson Reuters StreetEvents

6 months ago

Q4 2024 Mersana Therapeutics Inc Earnings Call

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

Zacks

6 months ago

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Tops Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire

6 months ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2024 Financial Results

What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings

GuruFocus.com

6 months ago

What To Expect From Mersana Therapeutics Inc (MRSN) Q4 2024 Earnings

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

6 months ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

GlobeNewswire

7 months ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2024 Conference Call on March 3, 2025

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

7 months ago

Mersana Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

MT Newswires

7 months ago

William Blair Initiates Coverage on Mersana Therapeutics With Outperform Rating

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

GlobeNewswire

7 months ago

Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference

MT Newswires

8 months ago

Wedbush Cuts Price Target on Mersana Therapeutics to $4 From $7, Keeps Outperform Rating

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

Benzinga

8 months ago

Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

MT Newswires

8 months ago

Mersana Therapeutics' XMT-1660 Gains Additional US FDA Fast Track Designation

MT Newswires

8 months ago

Mersana Therapeutics Says Initial Data From Cancer Drug Trial Shows Promise, Shares Rise Premarket

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

GlobeNewswire

8 months ago

Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660)

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

GlobeNewswire

8 months ago

Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer

Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

GuruFocus.com

10 months ago

Mersana Therapeutics Inc (MRSN) Q3 2024 Earnings Call Highlights: Strategic Advances and ...

Thomson Reuters StreetEvents

10 months ago

Q3 2024 Mersana Therapeutics Inc Earnings Call

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

Zacks

10 months ago

Mersana Therapeutics, Inc. (MRSN) Reports Q3 Loss, Tops Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

GlobeNewswire

10 months ago

Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

GlobeNewswire

10 months ago

Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024

SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc

GuruFocus.com

a year ago

SILVERARC CAPITAL MANAGEMENT, LLC Reduces Stake in Mersana Therapeutics Inc

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

a year ago

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

Zacks

a year ago

Mersana Therapeutics, Inc. (MRSN) Reports Q2 Loss, Misses Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

GlobeNewswire

a year ago

Mersana Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

GlobeNewswire

a year ago

Mersana Therapeutics to Host Second Quarter 2024 Conference Call on August 13, 2024

Mersana Therapeutics (NASDAQ:MRSN) shareholders have endured a 83% loss from investing in the stock three years ago

Simply Wall St.

a year ago

Mersana Therapeutics (NASDAQ:MRSN) shareholders have endured a 83% loss from investing in the stock three years ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

Yahoo Finance Video

a year ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

GlobeNewswire

a year ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

Reuters

a year ago

California seeks company profits in Big Oil climate lawsuit

USA TODAY

a year ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Business Wire

a year ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

GlobeNewswire

a year ago

Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

GlobeNewswire

a year ago

Global Polycaprolactone Market to Record Revenue Worth US$ 1535.5 Mn by 2034; Anticipated to Experience CAGR of 10.3% During 2024 – 2034; states TNR, The Niche Research

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Business Wire

a year ago

Media Advisory: Federal Housing Finance Agency Director Sandra Thompson Visits Affordable Apartment Complex in Dallas

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Business Wire

a year ago

Engelhart Commodities Trading Partners Agrees to Acquire Trailstone, Strengthening Commitment to the Energy Transition

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

GlobeNewswire

a year ago

Delfi Meedia, a subsidiary of AS Ekspress Grupp to acquire business operations of Eesti Koolitus- ja Konverentsikeskus

Share buy-back programme - week 23

GlobeNewswire

a year ago

Share buy-back programme - week 23

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Simply Wall St.

a year ago

Do Scientex Berhad's (KLSE:SCIENTX) Earnings Warrant Your Attention?

Japan's service sector mood hits nearly 2-year low in May

Reuters

a year ago

Japan's service sector mood hits nearly 2-year low in May

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

AFP

a year ago

N. Korea sends more balloons as Kim's sister warns of 'new counteraction'

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

GlobeNewswire

a year ago

Velcan Holdings: buyback offer of 500 000 shares at Eur 14.5 per share

Enduring role of 'treasuring the past' hailed

PR Newswire

a year ago

Enduring role of 'treasuring the past' hailed

See's Candies® Launches New Scotchmallow® Littles

PR Newswire

a year ago

See's Candies® Launches New Scotchmallow® Littles

Stock futures slip as markets digest hot jobs data

Yahoo Finance Video

a year ago

Stock futures slip as markets digest hot jobs data

IBHS honors resilient construction trailblazers

PR Newswire

a year ago

IBHS honors resilient construction trailblazers

SOUTHWEST AIRLINES RANKED TOP AIRLINE ON FORBES AMERICA'S BEST EMPLOYERS FOR VETERANS LIST

PR Newswire

a year ago

SOUTHWEST AIRLINES RANKED TOP AIRLINE ON FORBES AMERICA'S BEST EMPLOYERS FOR VETERANS LIST

Lyft Stock Rides High On Bullish Double-Upgrade After Company Offers New Growth Targets

Investor's Business Daily

a year ago

Lyft Stock Rides High On Bullish Double-Upgrade After Company Offers New Growth Targets

Benzinga

a year ago

Bill Gates Could Be The World's First Trillionaire If He Had 'Diamond Handed' His Microsoft Shares — He'd Be Sitting On $1.47 Trillion Today

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.

ACCESSWIRE

a year ago

Argus Research Updated Equity Report Coverage On Tego Cyber Inc.

Kohler Mira Ltd. Celebrates Mental Health Awareness Week in the UK: Promoting Wellbeing and Sharing Healthy Habits

ACCESSWIRE

a year ago

Kohler Mira Ltd. Celebrates Mental Health Awareness Week in the UK: Promoting Wellbeing and Sharing Healthy Habits

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

a year ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Simply Wall St.

a year ago

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript

Insider Monkey

a year ago

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q1 2024 Earnings Call Transcript

GuruFocus.com

a year ago

Mersana Therapeutics Inc (MRSN) Reports Q1 2024 Financial Results: A Detailed Analysis

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates

Zacks

a year ago

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Misses Revenue Estimates

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

GlobeNewswire

a year ago

Mersana Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

GlobeNewswire

a year ago

Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

Zacks

a year ago

Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire

a year ago

Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript

Insider Monkey

2 years ago

Mersana Therapeutics, Inc. (NASDAQ:MRSN) Q4 2023 Earnings Call Transcript

An Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% Undervalued

Simply Wall St.

2 years ago

An Intrinsic Calculation For Mersana Therapeutics, Inc. (NASDAQ:MRSN) Suggests It's 26% Undervalued

Mersana Therapeutics Full Year 2023 Earnings: Revenues Disappoint

Simply Wall St.

2 years ago

Mersana Therapeutics Full Year 2023 Earnings: Revenues Disappoint

Thomson Reuters StreetEvents

2 years ago

Q4 2023 Mersana Therapeutics Inc Earnings Call

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates

Zacks

2 years ago

Mersana Therapeutics, Inc. (MRSN) Reports Q4 Loss, Lags Revenue Estimates

Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results

GuruFocus.com

2 years ago

Mersana Therapeutics Inc (MRSN) Reports Fourth Quarter and Full Year 2023 Financial Results

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

GlobeNewswire

2 years ago

Mersana Therapeutics Provides Business Update and Announces Fourth Quarter and Full Year 2023 Financial Results

Mersana Therapeutics to Present at Upcoming Investor Conferences

GlobeNewswire

2 years ago

Mersana Therapeutics to Present at Upcoming Investor Conferences

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

Zacks

2 years ago

Stoke Therapeutics, Inc. (STOK) Expected to Beat Earnings Estimates: Should You Buy?

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

GlobeNewswire

2 years ago

Mersana Therapeutics to Host Fourth Quarter and Year End 2023 Conference Call on February 28, 2024

Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Zacks

2 years ago

Mersana Therapeutics, Inc. (MRSN) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

5 Value Stock Buying Opportunities

Zacks

2 years ago

5 Value Stock Buying Opportunities

Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference

GlobeNewswire

2 years ago

Mersana Therapeutics to Participate in Guggenheim’s 6th Annual Biotechnology Conference

Is 2024 the Year for Utilities Stocks? 3 Top Sector Picks

InvestorPlace

2 years ago

Is 2024 the Year for Utilities Stocks? 3 Top Sector Picks

Is LSI Industries Inc. (NASDAQ:LYTS) Trading At A 44% Discount?

Simply Wall St.

2 years ago

Is LSI Industries Inc. (NASDAQ:LYTS) Trading At A 44% Discount?

Isabeau Levito edges Amber Glenn in figure skating nationals short program

NBC Sports

2 years ago

Isabeau Levito edges Amber Glenn in figure skating nationals short program

Independent Bank Corporation Reports 2023 Fourth Quarter Results

GlobeNewswire

2 years ago

Independent Bank Corporation Reports 2023 Fourth Quarter Results

The past five years for Oil States International (NYSE:OIS) investors has not been profitable

Simply Wall St.

2 years ago

The past five years for Oil States International (NYSE:OIS) investors has not been profitable

BlackBerry Stock Is Tumbling Tuesday: What's Going On?

Benzinga

2 years ago

BlackBerry Stock Is Tumbling Tuesday: What's Going On?

NGL Energy Partners LP Announces $2.1 Billion Offering of Senior Secured Notes

Business Wire

2 years ago

NGL Energy Partners LP Announces $2.1 Billion Offering of Senior Secured Notes

11 Best MLP Dividend Stocks To Buy

Insider Monkey

2 years ago

11 Best MLP Dividend Stocks To Buy

Share on Social Networks: